REFERENCES

1. Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet 2010;376:1498-509.

2. Bowman ZS, Wiinsche V, Porter TF, Silver RM, Branch DW Prevalence of antiphospholipid antibodies and risk of subse­quent adverse obstetric outcomes in women with prior preg­nancy loss.

3. Cervera R, Font J, Khamashta MA, et al. Antiphospholipid syn­drome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002;46:1019-27.

4. Cohen D, Berger SP, Steup-Beekman GM, et al. Diagnosis and man­agement ofthe antiphospholipid syndrome. BMJ 2010;340:1125-32.

5. Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mor­tality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009;68:1428-32.

6. Alijotas-Reig J, Vilardell-Tarres M. Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid anti­bodies? Obstet Gynecol Surv 2010;65:39-45.

7. Alijotas-Reig J. The complement system as a main actor in the pathogenesis of obstetric antiphospholipid syndrome. Med Clin (Barc) 2010;134:30-34.

8. Stone S, Khamashta MA, Poston L. Placentation, antiphospholipid syndrome and pregnancy outcome. Lupus 2001;10:67-74.

9. Girardi G, Mackman N. Tissue factor in antiphospholipid anti­body-induced pregnancy loss: a pro-inflammatory molecule. Lupus 2008;17:931-36.

10. Cohen D, Berger SP, Steup-Beekman GM, et al. Diagnosis and management of the antiphospholipid syndrome. BMJ 2010;340:1125-32.

11. Bick RL. Antiphospholipid syndrome in pregnancy. Hematol Oncol Clin North Am 2008;22:107-20.

12. Clark EA, Silver RM, Branch DW Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome? Curr Rheumatol Rep 2007;9:219-25.

13. Ruffatti A, Bagatella P, Pengo V Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 2009;123:482-87.

14. Miyakis S, Lockshin MD, Atsumi T, et al. International con­sensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.

15. Silver RM, Heuser CC. Stillbirth workup and delivery manage­ment. Clin Obstet Gynecol 2010;53:681-90.

16. Silver RM, Heuser CC. Stillbirth workup and delivery manage­ment. Clin Obstet Gynecol 2010;53:681-90.

17. Ruiz-I rastorza G, Khamashta MA. Lupus and pregnancy: ten questions and some answers. Lupus 2008;17:416-20.

18. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141 Suppl 2:e691S-736S.

19. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syn­drome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002;100:408-13.

20. Lynch A, Marlar R, Murphy J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med 1994;120:470-75.

21. Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight hep­arin and aspirin for recurrent pregnancy loss: results from the ran­domized, controlled HepASA Trial. J Rheumatol 2009;36:279-87.

22. Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancyloss: a system­atic review and meta-analysis. Obstet Gynecol 2010;115:1256-62.

23. Mak A, Cheung MW, Cheak AA, et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospho­lipid antibodies: a meta-analysis of randomized controlled trials and meta-regression.

24. Kamel H, Navi BB, Sriram N, et al. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med 2014;370:1307-15.

25. Cnossen JS, Morris RK, ter Riet G, et al. Use of uterine artery Doppler ultrasonography to predict pre-e clampsia and intra­uterine growth restriction: a systematic review and bivariable meta-analysis. Can Med Assoc J 2008;178:701-11.

26. Le Thi Huong D, Wechsler B, Vauthier-Brouzes D, et al. The second trimester Doppler ultrasound examination is the best pre­dictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. Rheumatology (Oxford) 2006;45:332-38.

27. Faculty of Sexual and Reproductive Health Care. UK Medical Eligibility Criteria for Contraceptive Use (UK MEC). 2009. Available at: http://www.fsrh.org/admin/uploads/UKMEC2009. pdf.

28. 0stensen M, Khamashta M, Lockshin M, et al. Anti-inflamma­tory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006;8:209.

29. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-92.

30. Levi M, van der Poll T. Disseminated intravascular coagulation: a review for the internist. Intern Emerg Med 2013;8:23-32.

31. Rattray DD, O’Connell CM, Baskett TF. Acute disseminated intra­vascular coagulation in obstetrics: a tertiary centre population re­view (1980 to 2009). J Obstet Gynaecol Can 2012;34:341-47.

32. Erez O, Novack L, Beer-Weisel R, et al. DIC score in pregnant women—a population based modification ofthe International Society on Thrombosis and Hemostasis score. PLoS One 2014;9:e93240.

33. Mallaiah S, Barclay P, Harrod I, Chevannes C, Bhalla A. Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage. Anaesthesia 2015;70:166-75.

34. Mercier FJ, Bonnet MP. Use of clotting factors and other prohemostatic drugs for obstetric hemorrhage. Curr Opin Anaesthesiol 2010;23:310-16.

35.

36. Franchini M, Franchi M, Bergamini V, et al. The use of recom­binant activated FVII in postpartum haemorrhage. Clin Obstet Gynecol 2010;53:219-27.

37. Franchini M, Lippi G, Franchini M. The use of recombinant ac­tivated factor VII in obstetric and gynaecological haemorrhage. BJOG 2007;114:8-15.

38. Rodeghiero F, Castaman G, Dini E. Epidemiological inves­tigation of the prevalence of von Willebrand’s disease. Blood 1987;69:454-59.

39. Werner EJ, Broxson EH, Tucker EL, et al. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993;123:893-98.

40. Kadir RA, Lee CA, Sabin CA, et al. Pregnancy in women with von Willebrand’s disease or factor XI deficiency. Br J Obstet Gynaecol 1998;105:314-21.

41. James AH, Jamison MG. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost 2007;5:1165-69.

42. Kadir RA, Economides DL, Braithwaite J, et al. The obstetric experience of carriers of haemophilia. Br J Obstet Gynaecol 1997;104:803-10.

43. Chi C, Lee CA, Shiltagh N, et al. Pregnancy in carriers of haemo­philia. Haemophilia 2008;14:56-64.

44. Guy GP, Baxi LV, Hurlet-Jensen A, et al. An unusual complication in a gravida with factor IX deficiency: case report with review of the literature. Obstet Gynecol 1992;80:502-505.

45. Varekamp I, Suurmeijer TP, Brocker-Vriends AH, et al. Carrier testing and prenatal diagnosis for hemophilia: experiences and attitudes of 549 potential and obligate carriers. Am J Med Genet 1990;37:147-54.

46. Pachydakis A, Belgaumkar P, Sharmah A. Persistent scalp bleeding due to fetal coagulopathy following fetal blood sampling. Int J Gynaecol Obstet 2006;92:69-70.

47. Ljung R, Lindgren AC, Petrini P, et al. Normal vaginal delivery is to be recommended for haemophilia carrier gravidae.

48. Kadir RA, Economides DL, Braithwaite J, et al. The obstetric experience of carriers of haemophilia. Br J Obstet Gynaecol 1997;104:803-10.

49. Greer IA, Lowe GD, Walker JJ, et al. Haemorrhagic prob­lems in obstetrics and gynaecology in patients with congenital coagulopathies. Br J Obstet Gynaecol 1991;98:909-18.

50. Chi C, Lee CA, Shiltagh N, et al. Pregnancy in carriers of haemo­philia. Haemophilia 2008;14:56-64.

51. Chi C, Lee CA, England A, et al. Obstetric analgesia and an­aesthesia in women with inherited bleeding disorders. Thromb Haemost 2009;101:1104-11.

52. Conti M, Mari D, Conti E, et al. Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol 1986;68:282-85.

53. Roque H, Funai E, Lockwood CJ. von Willebrand disease and pregnancy. J Matern Fetal Med 2000;9:257-66.

54. Hoveyda F, MacKenzie IZ. Secondary postpartum haemor­rhage: incidence, morbidity and current management. BJOG 2001;108:927-30.

55. Chi C, Bapir M, Lee CA, Kadir RA. Puerperal loss (lochia) in women with or without inherited bleeding disorders. Am J Obstet Gynecol 2010;203:56.e1-56.

56. Lee CA, Chi C, Pavord SR, et al. The obstetric and gynaecological management of women with inherited bleeding disorders: re­view with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization. Haemophilia 2006;12:301-36.

57. Weisz B, Meirow D, Schiff E, et al. Impact and treatment of cancer during pregnancy. Exper Rev Anticancer Ther 2004;4:889-902.

58. Cohen-Kerem R, Railton C, Oren D, et al. Pregnancy outcome following non obstetric surgical intervention. Am J Surgery 2005;190:467-73.

59. Pacifici GM, Nottoli R. Placental transfer of drugs administered to the mother. Clin Pharmacokinet 1995;28:235-69.

60. Doll DC, Ringenberg QS, Yarbro JW Management of cancer during pregnancy. Arch Intern Med 1998;148:2058-64.

61. Randall T. National registry seeks scarce data on pregnancy out­comes during chemotherapy.

62. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004;5:283-91.

63. Aviles A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma 2001;2:173-77.

64. Nulman I, Laslo D, Fried S, et al. Neurodevelopment of children exposed in utero to treatment of maternal malignancy. Br J Cancer 2001;85:1611-18.

65. Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol 2005;6:328-33.

66. Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist 2002;7:279-87.

67. Lishner M, Zemlickis D, Degendorfer P, et al. Maternal and foetal outcome following Hodgkin’s disease in pregnancy. Br J Cancer 1992;65:114-17.

68. Hass JF. Pregnancy in association with a newly diagnosed cancer: a population based epidemiological assessment. Int J Cancer 1984;34:229-35.

69. Rizack T, Mega A, Legare R, et al. Management of haematological malignancies during pregnancy. Am J Hematol 2009;84:830-41.

70. Yang D, Hladnik L. Treatment of acute promyelocytic leukemia during pregnancy. Pharmacotherapy 2009;29:709-24.

71. Terada Y, Shindo T, Endoh A, et al. Fetal arrhythmia during treat­ment of pregnancy-a ssociated acute promyelocytic leukemia with all-t rans retinoic acid and favourable outcome. Leukemia 1997;11:454-55.

72. Cortes J. Natural history and staging of chronic myelogenous leu­kaemia. Haematol Oncol Clin North Am 2004;18:569-84.

73. Leung TN, Lau TK, Chung TKH. Thalassaemia screening in preg­nancy. Curr Opin Obstet Gynecol 2005;17:129-34.

74. Kham SK, Quah TC, Loong AM, et al. A molecular epidemiologic study of thalassaemia using newborns’ cord blood in a multiracial Asian population in Singapore: results and recommendations for a population screening program. J Pediatr Hematol Oncol 2004;26:817-19.

75. Old JM. Screening and genetic diagnosis of haemoglobin dis­orders. Blood Rev 2003;17:43-53.

76. Cao A, Galanello R. Beta-thalassaemia. GenetMed 2010;12:61-76.

77. Ryan K, Bain BJ, Worthington D, et al. Significant haemoglobinopathies: guidelines for screening and diagnosis. Br J Haematol 2010;149:35-49.

78. Lafferty JD, Crowther MA, Ali MA, et al. The evaluation ofvarious mathematical RBC indices and their efficacy in discriminating be­tween thalassemic and non-thalassemic microcytosis. Am J Clin Pathol 1996;106:201-205.

79. Lo YM, Chiu RW. Noninvasive approaches to prenatal diagnosis of hemoglobinopathies using fetal DNA in maternal plasma. Hematol Oncol Clin North Am 2010;24:1179-86.

80. Tongsong T, Wanapirak C, Sirichotiyakul S, et al. Fetal sono­graphic cardiothoracic ratio at midpregnancy as a predictor of Hb Bart disease. J Ultrasound Med 1999;18:807-11.

81. Ansari S, Kivan A, Tabaroki A. Pregnancy in patients treated for beta thalassaemia major in two centers (Ali Asghar Children’s Hospital and Thalassaemia Clinic): outcome for mothers and newborn infants. Pediatr Hematol Oncol 2006;23:33-37.

82. Ibba RM, Zoppi MA, Floris M, et al. Neural tube defects in the offspring of thalassaemia carriers. FetalDiagn Ther 2003;18:5-7.

83. Shehata N, Burrows R, Kelton JG. Gestational thrombocytopenia. Clin Obstet Gynecol 1999;42:127-34.

84. Burrows RF, Kelton JG. Thrombocytopenia at delivery: a prospective survey of 6715 deliveries. Am J Obstet Gynecol 1990;42:327-34.

85. Levy JA, Murphy LD. Thrombocytopenia in pregnancy. J Am Board Fam Pract 2002;15:290-97.

86. Sullivan CA, Martin JN Jr. Management of the obstetric patient with thrombocytopenia. Clin Obstet Gynecol 1995;38:521-34.

87. McCrae KR. Thrombocytopenia in pregnancy: differential diag­nosis, pathogenesis and management. Blood Rev 2003;17:7-14.

88. James TR, Reid HL, Mullings AM. Are published standards for haematological indices in pregnancy applicable across popula­tions: an evaluation in healthy pregnant Jamaican women. BMC Pregnancy Childbirth 2008;8:8.

89. Strong J. Bleeding disorders in pregnancy. Curr Obstet Gynecol 2003;13:1-6.

90. McCrae KR. Thrombocytopenia in pregnancy. Haematology 2010;4:397-402.

91. Egbor M, Johnson A, Harris F, Makanjoula D, Shehata H. Pregnancy-associated atypical haemolytic uraemic syndrome in the postpartum period: a case report and review of the literature. Obstet Med 2011;4:83-85.

92. Harkness DR, Byrnes JJ, Lian EC, Williams WD, Hensley GT. Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA 1981;246:1931-33.

93. Swisher KK, Terrell DR, Vesely SK, Kremer Hovinga JA, Lammle B, George JN. Clinical outcomes after platelet transfusions in pa­tients with thrombotic thrombocytopenic purpura. Transfusion 2009;49:873-87.

94. Kaandorp S, Di Nisio M, Goddijn M, et al. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospho­lipid syndrome. Cochrane Database Syst Rev 2009; 1:CD004734.

95. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta analysis. Lancet 2003;361:901-908.

96. Bick RL. Recurrent miscarriage syndrome and infertility caused by blood coagulation protein or platelet defects. Hematol Oncol Clin North Am 2000; 14:1117-31.

97. Meinardi JR, Middeldorp S, de Kam P, et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 1999;130:737-39.

98. Balasch J, Reverter JC, Fabregues F, et al. First trimester repeated abortion is not associated with activated protein C resistance. Hum Reprod 1997;12:1094-97.

99. Urbanus RT, Derksen RH, de Groot PG. Current insight into diagnostics and pathophysiology of the antiphospholipid syn­drome. Blood Rev 2008;22:93-105.

100. Lassere M, Empson M. Treatment of antiphospholipid syndrome in pregnancy: a systematic review of randomized therapeutic trials. Thromb Res 2004;114:419-26.

101. Dawood F, Farquharson R, Quenby S, et al. Acquired activated protein C resistance maybe a risk factor for recurrent fetal loss. Fertil Steril 2003;80:649-50.

102. Rai R, Shelbak A, Cohen H, et al. Factor V Leiden and acquired activated protein C resistance among 1000 women with recur­rent miscarriage. Hum Reprod 2001;16:961-65.

103. Lindqvist PG, Svensson PJ, Marsaal K, et al. Activated pro­tein C resistance (FV: Q506) and pregnancy. Thromb Haemost 1999;81:532-37.

104. Jauniaux E, Farquharson RG, Christianson OB, et al. Evidence­based guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod 2006;21:2216-22.

105. Jaslow CR, Carney JL, Kutteh WH. Diagnostic factors identified in 1020 women with two verses three or more recurrent preg­nancy losses. Fertil Steril 2010;2009:1234-43.

106. Clark P, Walker ID, Langhorne P, et al. SPIN: the Scottish Pregnancy Intervention Study: a multi-centre randomized con­trol trial of low molecular weight heparin and low dose aspirin in women with recurrent miscarriage. Blood 2010;115:4162-67.

107. Kaandorp SP, Goddijn M, Van Der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010;362:1586-96.

108. Coppens M, Folkeringa N, Teune MJ, et al. Outcome ofsubsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A. Thromb Haemost 2007;5:1444-48.

109. American College of Obstetrics and Gynaecologists. ACOG practice bulletin. Management of recurrent pregnancy loss. Int J Gynaecol Obstet 2002;78:179-90.

110. Norrie G, Farquharson RG, Greaves M. Screening and treatment for heritable thrombophilia in pregnancy failure: inconsistencies among UK early pregnancy units. Br J Haematol 2008;144:241-44.

111. Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003;1:433-38.

112. Gris JC, Mares P. The long and winding road towards LMWH for pregnancy loss. J Thromb Haemost 2005;3:224-26.

113. Folkeringa N, Leendert J, Brouwer P, et al. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Haematol 2007;136: 656-61.

114. Lindqvist PG, Merlo J. The natural course of women with recur­rent fetal loss. J Thromb Haemost 2006;4:896-97.

115. Lindqvist PG, Svensson PJ, Marsaal K, et al. Activated pro­tein C resistance (FV: Q506) and pregnancy. Thromb Haemost 1999;81:532-37.

116. Rai R, Regan L. Recurrent miscarriage. Lancet 2006;368:601-11.

117. Rai RS, Clifford K, Cohen H, et al. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995;10:348-49.

118. Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009;36:279-87.

119. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syn­drome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002;100:408-13.

120. Brenner B. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications. Thromb Haemost 2003;1:2070-72.

121. Dawood F, Mountford R, Farquharson R, et al. Genetic polymorphisms on the factor V gene in women with recurrent miscarriage and acquired APCR. Hum Reprod 2007;22:2546-53.

122. Flint Porter T, La Coursiere Y, Scott JR. Immunotherapy for recur­rent miscarriage. Cochrane Database Syst Rev 2006;2:CD000112.

123. Laskin CA, Bombardier C, Hannah ME, et al. Prednisone and as­pirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997;368:148-53.

124. Triolo G, Ferrante A, Ciccia F, et al. Randomized study of sub­cutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003;48:728-31.

125. de Benoist B, Mclean E, Egli I, Cogswell M (eds). Worldwide Prevalence of Anaemia 1993- 2005: WHO Global Database on Anaemia. Geneva: World Health Organization; 2008.

126. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva: World Health Organization; 2011.

127. World Health Organization. Iron Deficiency Anaemia: Assessment Prevention and Contro. A Guide for Programme Managers. Geneva: World Health Organization; 2001.

128. Stevens GA, Finucane MM, De-Regil LM, et al. Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non­pregnant women for 1995-2011: a systematic analysis of popula­tion-representative data. Lancet Glob Health 2013;1:E16-E25.

129. Aslinia F, Mazza JJ, Yale SH. Megaloblastic anemia and other causes of macrocytosis. Clin Med Res 2006;4:236-41.

130. Gambling L, Danzeisen R, Gair S, et al. Effect of iron deficiency on placental transfer of iron and expression of iron transport pro­teins in vivo and in vitro. Biochem J 2001;356:883-89.

131. Pavord S, Myers B, Robinson S, et al, UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol 2012;156:588-600.

132. Shehata HA, Ali MM, Evans-Jones JC, Upton GJ, Manyonda IT. Red cell distribution width (RDW) changes in pregnancy. Int J Gynaecol Obstet 1998;62:43-46.

133. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997;89:1052-57.

134. United Nations Children’s Fund, United Nations University, World Health Organization. Iron DeficiencyAnaemia: Assessment, Prevention, and Control. A Guide for Programme Managers. Geneva: World Health Organization; 2001. Available at: http:// www.who.int/nutrition/publications/en/ida_assessment_pre- vention_control.pdf.

135. World Health Organization. Guideline: Daily Iron and Folic Acid Supplementation in Pregnant Women. Geneva: World Health Organization; 2012.

136. National Institute for Health and Care Excellence (NICE). Antenatal Care for Uncomplicated Pregnancies. Clinical guide­line [CG62], updated 2019. London: NICE; 2008. Available at: https://www.nice.org.uk/guidance/CG62.

137. Royal College of Obstetricians and Gynaecologists (RCOG). Blood Transfusions in Obstetrics. Green-top Guideline No. 47. London: RCOG; 2007.

138. Al RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A. Intravenous versus oral iron for treatment of anemia in preg­nancy: a randomized trial. Obstet Gynecol 2005;106:1335-40.

139. Bayoumeu F, Subiran-Buisset C, Baka N-E, Legagneur H, Monnier-Barbarino P, Laxenaire MC. Iron therapy in iron de­ficiency anaemia in pregnancy: Intravenous route versus oral route. Eur J Obstet Gynecol Reprod Biol 2005;123:S15-19.

140. Van Wyk DB, Martens MG. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anaemia: a randomized controlled trial. Obstet Gynecol 2007;110:267-78.

141. Solomons NW, Schumann K. Intramuscular administration of iron dextran is inappropriate for treatment of moderate preg­nancy anaemia, both in intervention research on underpriv­ileged women and in routine prenatal care provided by public health services. Am J Clin Nutr 2004;79:1-3.

142. Department of Health. Better Blood Transfusion - Safe and Appropriate Use of Blood. HSC 2007/001. London: Department of Health.

143. Scholl TO, Johnson WG. Folic acid: influence on the outcome of pregnancy. Am J Clin Nutr 2000;71 Suppl:1295S-303S

144. Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove P. Inherited disorders of haemoglobin. In: Jamison DT, Breman JG, Measham AR, et al. (eds), Disease Control Priorities in Developing Countries, 2nd edn, pp. 663-80. Washington, DC: The World Bank; 2006.

145. Angastiniotis M, Modell B, Englezos P, et al. Prevention and control of haemoglobinopathies. Bull World Health Organ 1995; 73:375-86.

146. Serjeant GR. Sickle cell disease. Lancet 1997;350:725-30.

147. Diallo D, Tchernia G. Sickle cell disease in Africa. Curr Opin Hematol 2002;9:111-16.

148. Streetley A, Latinovic R, Hall K, et al. Implementation of universal newborn bloodspot screening for sickle cell disease and other clinically significant haemoglobinopathies in England: screening results for 2005-7. J Clin Pathol 2009;62:26-30.

149. Telfer P, Coen P, Chakravorty S, et al. Clinical outcomes in chil­dren with sickle cell disease living in England: a neonatal cohort in East London. Haematologica 2007;92:905-12.

150. Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic based population study. Lancet 2001;357:680-83.

151. Villers MS, Jamison MG, De Castro LM, et al. Morbidity asso­ciated with sickle cell disease in pregnancy. Am J Obstet Gynecol 2008;199:125.e1-125.

152. Dare FO, Makinde OO, Faasuba OB. The obstetric performance of sickle cell disease patients and homozygous haemoglobin C disease patients in Ile-Ife Nigeria. Int J Gynaecol Obstet 1992;37:163-68.

153. Oteng-Ntim E, Ayensah B, Knight M, Howard J. Pregnancy out­come in patients with sickle cell disease in the UK—a national cohort study comparing sickle cell anaemia (HbSS) with HbSC disease. Br JHaematol 2015;169:129-37.

154. Al Jama FE, Gasem T, Burshaid S, et al. Pregnancy outcome in pa­tients with homozygous sickle cell disease in a university hospital, Eastern Saudi Arabia. Arch Gynecol Obstet 2009;280:793-97.

155. Rajab KE, Issa AA, Mohammed AM, et al. Sickle cell disease and pregnancy in Bahrain. Int J Gynecol Obstet 2006;93:171-75.

156. Ngo C, Kayem G, Habibi A, et al. Pregnancy in sickle cell dis­ease: maternal and fetal outcomes in a population receiving prophylactic partial exchange transfusions. Eur J Obstet Gynae Reprod Biol 2010;152:138-42.

157. Howard RJ, Tuck SM, Pearson TC. Pregnancy in sickle cell dis­ease in the UK: results of a multicentre survey of the effect of prophylactic blood transfusion on maternal and fetal outcome. Br J Obstet Gynaecol 1995;102:947-51.

158. Powars DR, Sandhu M, Niland-Weiss J, et al. Pregnancy in sickle cell disease. Obstet Gynecol 1986;67:217-28.

159. Sun PM, Wilburn W, Raynor BD, et al. Sickle cell disease in preg­nancy: twenty years of experience at Grady Memorial Hospital, Atlanta, Georgia. Am J Obstet Gynecol 2001;184:1127-39.

160. El Shafei AM, Sandhu AK, Dhaliwal JK. Maternal mortality in Bahrain with special reference to sickle cell disease. Aust NZ J Obstet Gynaecol 1988;28:41-44.

161. Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haem 2006;134:109-15.

162. Sickle Cell Society. Standards for the Clinical Care of Adults with Sickle Cell Disease in the UK. 2008. Available at: https://www. sicklecellsociety.org/resource/standards-clinical-care-adults- sickle-cell-disease-uk/standards-for-the-clinical-care-of-adults- with-sickle-cell-disease-in-the-uk/.

163. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxycarbamide on the frequency of painful crisis in SCD. N Engl J Med 1995;332:1317-22.

164. Lindenbaum J, Klipstein FA. Folic acid deficiency in sickle cell anaemia. N Engl J Med 1963;269:875-82.

165. Duley L, Henderson-Smart DJ, Meher S, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007;2:CD004659.

166. Villers MS, Jamison MG, De Castro LM, et al. Morbidity asso­ciated with sickle cell disease in pregnancy. Am J Obstet Gynecol 2008;199:125.e1-125.e5.

167. National Institute of Health and Clinical Excellence (NICE). The Management of Hypertensive Disorders during Pregnancy. Clinical guidelines [CG107]. London: NICE; 2010. Available at: https://www.nice.org.uk/guidance/cg107.

168. Cunningham FG, Pritchard JA. Prophylactic transfusions of normal red blood cells during pregnancies complicated by sickle cell hemoglobinopathies. Am J Obstet Gynecol 1975;135:994-1003.

169. Koshy M, Burd L, Wallace D, et al. Prophylactic red cell transfusions in pregnant patients with sickle cell disease. N Engl J Med 1988;319:1447-52.

170. Mahomed K. Prophylactic versus selective blood transfusion for sickle cell anaemia during pregnancy. Cochrane Database Syst Rev 2007;3:CD000040.

171. El Shafei AM, Sandhu AK, Dhaliwal JK. Maternal mortality in Bahrain with special reference to sickle cell disease. Aust NZ J Obstet Gynaecol 1988;28:41-44.

172. Anyaegbunam A, Morel MI, Merkatz IR. Antepartum fetal surveillance tests during sickle cell crisis. Am J Obstet Gynecol 1991;165:1081-83.

173. Anyaegbunam A, Mikhail M, Axioitis C, et al. Placental histology and placental/fetal weight ratios in pregnant women with sickle cell disease: relationship to pregnancy outcome. J Assoc Acad Minor Phys 1994;5:123-25.

174. Royal College of Obstetricians and Gynaecologists (RCOG). Reducingthe Risk OfThrombosisandEmbolism duringPregnancyand the Puerperium. Green-top Guideline No. 37(A). London: RCOG; 2009.

175. Howard RJ, Tuck SM, Pearson TC. Pregnancy in sickle cell dis­ease in the UK: results of a multicentre survey of the effect of prophylactic blood transfusion on maternal and fetal outcome. Br J Obstet Gynaecol 1995;102:947-51.

176. Camous J, N’da A, Etienne-Julan M, et al. Anesthetic manage­ment of pregnant women with sickle cell disease—effect on post­natal sickling complications. Can JAnesth 2008;55:276-83.

177. Legardy JK, Curtis KM. Progestogen-only contraceptive use among women with sickle cell anaemia, a systematic review. Contraception 2006;73:195-204.

178. Al Jama FE, Gasem T, Burshaid S, et al. Pregnancy outcome in pa­tients with homozygous sickle cell disease in a university hospital, Eastern Saudi Arabia. Arch Gynecol Obstet 2009;280:793-97.

179. Howard RJ, Tuck SM, Pearson TC. Pregnancy in sickle cell dis­ease in the UK: results of a multicentre survey of the effect of prophylactic blood transfusion on maternal and fetal outcome. Br J Obstet Gynaecol 1995;102:947-51.

180. Rees DC, Olujohungbe AD, Parker NE, et al. Guidelines for the management of acute painful crisis in sickle cell disease. Br J Haematol 2003;120:744-52.

181. Serjeant GR, Loy LL, Crowther M, et al. Outcome of preg­nancy in homozygous sickle cell disease. Obstet Gynaecol 2004;103:1278-85.

182. Howard RJ, Tuck SM, Pearson TC. Pregnancy in sickle cell dis­ease in the UK: results of a multicentre survey of the effect of prophylactic blood transfusion on maternal and fetal outcome. Br J Obstet Gynaecol 1995;102:947-51.

183. Smith JA, Espeland M, Bellevue R, et al. Pregnancy in sickle cell disease: experience of the cooperative study of sickle cell disease. Obstet Gynaecol 1996;87:199-204.

184. Ohene- Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in SCD: rates and risk factors. Blood 1998;91:288-94.